You are currently viewing CB Therapeutics Expands Biomanufacturing IP Portfolio

CB Therapeutics Expands Biomanufacturing IP Portfolio

  • CB Therapeutics has been awarded two additional patents for its breakthrough biosynthesis platform.
  • These patents cover new cellular agriculture advances for producing high value compounds.
  • CB Therapeutics is building the largest collection of biosynthetic cannabinoids, psychedelics, and their analogs, the PsyVault™.

SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is a leading biosynthesis company focused on the research and development of environmentally-friendly products to improve mental health, increase healthspan, and promote longevity.

CB Therapeutics is happy to announce that it has been awarded two more patents for the novel methods of production of high value molecules using cutting-edge biosynthesis technologies. These patents (11,041,002B1 and 10,988,785B1) cover inventions on cellular agriculture breakthroughs for producing cannabinoids and precursors to various other compounds, including those in the burgeoning psychedelic space.

“We are very excited about these patent awards. With the growing mental health crisis, the ability to generate pure, sustainable, and scalable therapeutics is more important than ever,” said Dr. Jacob Vogan, CSO of CB Therapeutics. “Everyone deserves a healthy, fulfilling life. We’re proud to be at the forefront of a new biomanufacturing revolution, producing compounds with great potential to improve wellbeing, and to do so without a detrimental impact on the environment.”

“We have always been focused on generating value for the good of society and our investors. As a leader in synthetic biology of the cannabinoid, psychedelic, and other spaces, we continue to gain validation of our bioplatform. We are dedicated to the development of new therapeutics, the improvement of sustainable processes, and the technologies that streamline the validation and production of new molecules. Our recent Series A funding enabled us to expand our capabilities and brilliant team. We’ll be developing molecules quicker than ever before, as we have dramatically enhanced our ability to work on many important projects in parallel,” said Sher Ali Butt, CEO of CB Therapeutics.

About CB Therapeutics

CB Therapeutics is currently producing high value molecules, compounds and rare ingredients from simple sugars utilizing yeast and the process of fermentation. CB Therapeutics’ expertise in synthetic genomics and bio-engineering has significantly advanced its proprietary production platform of microorganisms, enzymes and production processes. After more than four years of research and development, the CB Therapeutics team is able to produce a broad range of phytochemicals faster, utilizing fewer resources, at greater yields and with more purity, consistency and efficiency than competing platforms. Its 7000+ sf fully-licensed commercial batch facility in San Diego County, California includes research labs, offices and a production facility for laboratory scale and pilot production runs and is equipped with a suite of bench-top and large-scale fermenters for multiple biosynthetic production applications.